Ascentage Pharma Group International
HKEX:6855
Ascentage Pharma Group International
HKEX:6855
Price:
18.4 HKD
-1.81%
Market Closed
Updated:
May 6, 2024
Income Statement
Earnings Waterfall
Ascentage Pharma Group International
Ascentage Pharma Group International
|
Revenue
|
222m
CNY
|
|
Cost of Revenue
|
-30.5m
CNY
|
|
Gross Profit
|
191.4m
CNY
|
|
Operating Expenses
|
-1.1B
CNY
|
|
Operating Income
|
-874m
CNY
|
|
Other Expenses
|
-51.6m
CNY
|
|
Net Income
|
-925.6m
CNY
|
Income Statement
Ascentage Pharma Group International
Ascentage Pharma Group International
Currency: CNY
| Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||
| Revenue |
15
N/A
|
15
+2%
|
12
-16%
|
23
+83%
|
28
+22%
|
111
+297%
|
210
+89%
|
257
+22%
|
222
-14%
|
|
| Gross Profit | ||||||||||
| Cost of Revenue |
(2)
|
0
|
(2)
|
(5)
|
(3)
|
(6)
|
(22)
|
(35)
|
(31)
|
|
| Gross Profit |
12
N/A
|
0
N/A
|
10
N/A
|
18
+74%
|
25
+35%
|
105
+327%
|
188
+79%
|
222
+18%
|
191
-14%
|
|
| Operating Income | ||||||||||
| Operating Expenses |
(1 473)
|
(1 198)
|
(698)
|
(756)
|
(918)
|
(1 059)
|
(1 041)
|
(1 036)
|
(1 065)
|
|
| Selling, General & Administrative |
(162)
|
(162)
|
(130)
|
(143)
|
(191)
|
(270)
|
(328)
|
(349)
|
(376)
|
|
| Research & Development |
(464)
|
(516)
|
(565)
|
(631)
|
(766)
|
(790)
|
(743)
|
(712)
|
(707)
|
|
| Other Operating Expenses |
(848)
|
(520)
|
(3)
|
18
|
40
|
2
|
30
|
25
|
18
|
|
| Operating Income |
(1 461)
N/A
|
(1 183)
+19%
|
(688)
+42%
|
(737)
-7%
|
(893)
-21%
|
(954)
-7%
|
(853)
+11%
|
(814)
+5%
|
(874)
-7%
|
|
| Pre-Tax Income | ||||||||||
| Interest Income Expense |
(22)
|
15
|
12
|
7
|
61
|
92
|
(36)
|
(70)
|
(59)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
(0)
|
0
|
|
| Pre-Tax Income |
(1 482)
N/A
|
(1 168)
+21%
|
(675)
+42%
|
(730)
-8%
|
(832)
-14%
|
(860)
-3%
|
(887)
-3%
|
(885)
+0%
|
(933)
-5%
|
|
| Net Income | ||||||||||
| Tax Provision |
2
|
2
|
(2)
|
(5)
|
50
|
48
|
4
|
6
|
7
|
|
| Income from Continuing Operations |
(1 481)
|
(1 167)
|
(678)
|
(735)
|
(782)
|
(812)
|
(883)
|
(879)
|
(926)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
|
| Net Income (Common) |
(1 481)
N/A
|
(1 167)
+21%
|
(678)
+42%
|
(735)
-8%
|
(782)
-6%
|
(812)
-4%
|
(883)
-9%
|
(879)
+0%
|
(926)
-5%
|
|
| EPS (Diluted) |
-12.69
N/A
|
-5.58
+56%
|
-3.14
+44%
|
-2.97
+5%
|
-3.07
-3%
|
-3.09
-1%
|
-3.35
-8%
|
-3.19
+5%
|
-3.28
-3%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
